Drug intelligence / Profile preview

CARC-101C

Development stage: Phase 1
Lead developer: Carcell Biopharma

Overview

CARC-101C is an investigational drug being developed by Carcell Biopharma for the treatment of autoimmune type 1 diabetes mellitus (T1DM). It is classified as a new molecular entity and is currently in early clinical development, with preclinical and early phase 1 studies underway. The precise mechanism of action has not been disclosed or defined publicly. The drug is being evaluated in open-label, dose-escalation studies to assess its safety, pharmacokinetics, and preliminary efficacy in adults recently diagnosed with autoimmune type 1 diabetes who are on insulin therapy[1][2][3][4][5].

Beyond the preview

Go deeper on CARC-101C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CARC-101C.

Explore the full profile